X4 Pharmaceuticals Inc (XFOR)
0.5489
-0.02
(-2.76%)
USD |
NASDAQ |
Jul 05, 16:00
0.5498
0.00 (0.00%)
After-Hours: 20:00
X4 Pharmaceuticals Research and Development Expense (Annual): 72.02M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 72.02M |
| December 31, 2022 | 61.06M |
| December 31, 2021 | 50.65M |
| December 31, 2020 | 41.93M |
| December 31, 2019 | 30.16M |
| Date | Value |
|---|---|
| December 31, 2018 | 20.35M |
| December 31, 2017 | 28.13M |
| December 31, 2016 | 17.83M |
| December 31, 2015 | 12.71M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
30.16M
Minimum
2019
72.02M
Maximum
2023
51.16M
Average
50.65M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Amgen Inc | 4.784B |
| Ironwood Pharmaceuticals Inc | 116.08M |
| Ocular Therapeutix Inc | 61.06M |
| Scholar Rock Holding Corp | 121.90M |
| RAPT Therapeutics Inc | 101.00M |